Profusa Adds Head of Vascular Surgery Department at AZ Sint Blasius Hospital, Belgium to Growing Customer Base
Profusa (NASDAQ:PFSA), a digital health company, announces a new commercial and clinical collaboration with the Department of Vascular Surgery at AZ Sint Blasius Hospital, Belgium. The partnership is led by Dr. Koen Deloose, an internationally recognized vascular surgeon specializing in critical limb ischemia (CLTI).
Dr. Deloose, who treats over 300 CLTI patients annually, has successfully implemented Profusa's Lumee™ Oxygen measurement system for monitoring endovascular revascularization procedures. The technology provides real-time tissue oxygen perfusion metrics crucial for treatment success. Dr. Deloose's modern vascular clinic offers a multidisciplinary approach, combining expertise from diabetic foot specialists, wound care experts, and podiatrists.
Profusa (NASDAQ:PFSA), azienda nel settore della salute digitale, annuncia una nuova collaborazione commerciale e clinica con il Dipartimento di Chirurgia Vascolare dell'AZ Sint Blasius Hospital, Belgio. La partnership è guidata dal Dr. Koen Deloose, chirurgo vascolare di fama internazionale specializzato nell'ischemia critica degli arti (CLTI).
Il Dr. Deloose, che tratta oltre 300 pazienti CLTI all'anno, ha integrato con successo il sistema di misurazione dell'ossigeno Lumee™ di Profusa per il monitoraggio delle procedure di rivascolarizzazione endovascolare. La tecnologia fornisce metriche in tempo reale della perfusione tissutale in ossigeno, fondamentali per il successo terapeutico. Il suo ambulatorio vascolare all'avanguardia adotta un approccio multidisciplinare, coinvolgendo specialisti del piede diabetico, esperti di medicazione delle ferite e podologi.
Profusa (NASDAQ:PFSA), empresa de salud digital, anuncia una nueva colaboración comercial y clínica con el Departamento de Cirugía Vascular del AZ Sint Blasius Hospital, Bélgica. La alianza está liderada por el Dr. Koen Deloose, cirujano vascular de reconocimiento internacional especializado en isquemia crítica de las extremidades (CLTI).
El Dr. Deloose, que atiende a más de 300 pacientes con CLTI al año, ha implementado con éxito el sistema de medición de oxígeno Lumee™ de Profusa para monitorizar procedimientos de revascularización endovascular. La tecnología ofrece métricas de perfusión tisular en tiempo real, esenciales para el éxito del tratamiento. Su clínica vascular moderna aplica un enfoque multidisciplinario, integrando especialistas en pie diabético, expertos en cuidado de heridas y podólogos.
Profusa (NASDAQ:PFSA), 디지털 헬스 기업이 벨기에 AZ Sint Blasius 병원 혈관외과와 새로운 상업적·임상 협력을 발표했습니다. 이 파트너십은 말초동맥질환 및 중증 하지 허혈(CLT I) 전문의로 국제적으로 알려진 Dr. Koen Deloose가 이끌고 있습니다.
연간 300명 이상의 CLTI 환자를 진료하는 Dr. Deloose는 Profusa의 Lumee™ 산소 측정 시스템을 말초혈관 재관류(내혈관 재혈관술) 모니터링에 성공적으로 도입했습니다. 해당 기술은 치료 성패에 중요한 조직 산소 관류 지표를 실시간으로 제공합니다. 첨단 혈관 클리닉은 당뇨발 전문의, 상처 관리 전문가, 족부 전문의를 포함한 다학제적 접근을 채택하고 있습니다.
Profusa (NASDAQ:PFSA), entreprise de santé numérique, annonce une nouvelle collaboration commerciale et clinique avec le Département de chirurgie vasculaire de l'AZ Sint Blasius Hospital, Belgique. Le partenariat est dirigé par le Dr Koen Deloose, chirurgien vasculaire de renommée internationale spécialisé dans l'ischémie critique des membres (CLTI).
Le Dr Deloose, qui prend en charge plus de 300 patients CLTI par an, a mis en œuvre avec succès le système de mesure de l'oxygène Lumee™ de Profusa pour le suivi des procédures de revascularisation endovasculaire. La technologie fournit des indicateurs de perfusion tissulaire en oxygène en temps réel, essentiels au succès des traitements. Sa clinique vasculaire moderne adopte une approche multidisciplinaire, réunissant des spécialistes du pied diabétique, des experts en cicatrisation des plaies et des podologues.
Profusa (NASDAQ:PFSA), ein Digital-Health-Unternehmen, gibt eine neue kommerzielle und klinische Zusammenarbeit mit der Gefäßchirurgie des AZ Sint Blasius Hospital, Belgien bekannt. Die Partnerschaft wird von Dr. Koen Deloose geleitet, einem international anerkannten Gefäßchirurgen, der auf kritische Extremitätenischämie (CLTI) spezialisiert ist.
Dr. Deloose, der jährlich über 300 CLTI-Patienten behandelt, hat erfolgreich das Lumee™-Sauerstoffmesssystem von Profusa zur Überwachung endovaskulärer Revaskularisationsverfahren eingeführt. Die Technologie liefert in Echtzeit Metriken zur Gewebeoxygensättigung, die für den Behandlungserfolg entscheidend sind. Seine moderne Gefäßklinik verfolgt einen multidisziplinären Ansatz und bündelt Expertise von Diabetischem-Fuß-Spezialisten, Wundversorgungs-Expert:innen und Podolog:innen.
- Expansion of customer base in European market with new prestigious medical center
- Validation of Lumee™ technology by internationally recognized vascular surgeon
- Integration into treatment of large patient population (300+ CLTI patients annually)
- Partnership with influential medical leader who has authored 200+ peer-reviewed articles
- None.
Insights
Profusa expands European presence with key opinion leader adoption, signaling clinical validation but limited immediate revenue impact.
Profusa's new collaboration with Dr. Koen Deloose represents a strategic expansion of its European commercialization efforts for its Lumee™ Oxygen monitoring platform. The significance lies not just in adding another customer, but in the clinical validation from a recognized key opinion leader in vascular surgery who treats over 300 critical limb ischemia patients annually.
Dr. Deloose's endorsement provides valuable clinical credibility, stating he's "convinced this technology will offer more guidance" for CLTI treatment. This validation is particularly meaningful given his professional standing - authoring over 200 peer-reviewed articles, serving as CMO of a clinical research organization, and holding leadership positions in European medical conferences.
From a commercial perspective, this represents incremental progress rather than transformative growth. The partnership with a single physician/hospital will have limited immediate revenue impact. However, it establishes a potential reference site for the Lumee system in treating critical limb ischemia, a condition affecting approximately 2-3% of peripheral artery disease patients over 50.
The collaboration's true value lies in building evidence for Profusa's tissue oxygen sensing technology in a specialized clinical setting, potentially accelerating broader adoption among vascular surgeons treating this "constantly growing CLTI-population." This aligns with the company's strategy to progress "target indications" of their platform technology through clinical validation.
Internationally recognized vascular surgeon, Dr. Koen Deloose provides patient access to latest innovative treatments and personalized care
BERKELEY, Calif, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the continuous monitoring of an individual’s biochemistry, announces continued growth in its customer base in Europe, with a new commercial and clinical collaboration with the Department of Vascular Surgery at AZ Sint Blasius Hospital, Belgium. Koen R. Deloose, M.D., BSVS, head of the department, is an internationally recognized vascular surgeon specializing in critical limb ischemia (“CLTI”) with over 300 CLTI patients treated annually and will spearhead the collaboration at the key center. Dr. Deloose also serves in leadership roles at a clinic research organization (“CRO”) and in major European medical conferences.
“I personally used the Lumee™ Oxygen measurement to monitor endovascular revascularization procedures in below the knee cases. Profusa’s technology provides a critical real-time tissue oxygen perfusion metric that is essential for our successful treatment of these patients,” said Dr. Deloose. “My case data highlighted the relationships between oxygen dynamics measured at point locations, anatomical target of delivered interventions, and treatment outcome. I’m convinced this technology will offer us more guidance in the treatment and follow-up of a constantly growing CLTI-population.”
Dr. Deloose recently opened a modern vascular clinic with a multidisciplinary approach that includes diabetic foot specialists, wound care experts and podiatrists, to provide patient access to the latest treatments and personalized care. Dr. Deloose is chief medical officer of the CRO Kando Research, focusing on advancing vascular medicine and providing patients with early access to innovative technologies. He is also founding co-course director and board member of the organizing committee of Paris Vascular Insights and a member of the EVC Maastricht board. As an active researcher, Dr. Deloose has authored and co-authored more than 200 articles in peer-reviewed medical journals, more than 10 chapters in orthopedic, vascular and endovascular books, and is editorial board member of the Journal of Cardiovascular Surgery and the Journal of Critical Limb Ischemia, Endovascular Section.
"We continue to add to our impressive roster of customers and warmly welcome Dr. Deloose to our network. The combination of Dr. Deloose’s clinical approach and CLTI research programs that advance the campaign against major amputations due to vascular and arterial diseases speaks to Profusa’s mission to make our body's chemistry easily accessible, improving health and wellness,” said Ben Hwang, Ph.D., Profusa’s Chairman and CEO. “We look forward to contributing to Dr. Deloose’s clinical agenda with our Lumee Oxygen monitoring system and to future collaborations as we progress target indications of our platform technology.”
About Profusa
Based in Berkeley, Calif., Profusa is a commercial stage digital health company led by visionary scientific founders, an experienced management team and a world-class board of directors in the development of a new generation of tissue-integrated sensors to detect and continuously transmit actionable, medical-grade data for personal and medical use. With its long-lasting, injectable and affordable biosensors and its intelligent data platform, Profusa aims to provide people with a personalized biochemical signature rooted in data that clinicians can trust and rely on.
“LUMEE”, “PROFUSA” and the PROFUSA logo are registered trademarks of Profusa Inc. in the United States, Canada, European Union, China, Japan, South Korea and Australia.
For more information, visit https://profusa.com.
Special Note Regarding Forward-Looking Statements
Certain statements in this press release (this “Press Release”) may be considered “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or future financial or operating performance of Profusa or the combined company. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “propose,” “seek,” “should,” “strive,” “will,” or “would” or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which may be beyond the control of Profusa and could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Profusa and its management are inherently uncertain. Profusa cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. There are risks and uncertainties described in the definitive proxy/final prospectus relating to the business combination, which has been filed with the SEC, and in other documents filed by Profusa from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Profusa cannot assure you that the forward-looking statements in this communication will prove to be accurate.
Contacts
Investor and Media Contacts
email: info@coreir.com
phone: 1 (212) 655-0924
FAQ
What is the new partnership announced by Profusa (PFSA)?
How is Profusa's Lumee™ Oxygen measurement system being used in CLTI treatment?
Who is Dr. Koen Deloose and why is this partnership significant for Profusa?
What services does Dr. Deloose's vascular clinic offer?
How does this partnership align with Profusa's mission?
